Unlock instant, AI-driven research and patent intelligence for your innovation.

Stable topical drug delivery compositions

A composition, stable technology, applied in the direction of drug combination, drug delivery, pharmaceutical formulation, etc., can solve the problem of inability to store or carry

Inactive Publication Date: 2006-02-08
TRANSDERMAL BIOTECHNOLOGY INC
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Said substance cannot be stored or carried by the user (without refrigeration)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Stable insulin topical formulations are formulated by first preparing a base solution. The polyalkenylphosphatidylcholine material designated NAT8729 was obtained from Rhone-Poulenc and contained 80.6% PPC-enriched phosphatidylcholine and 4.9% lysophosphatidylcholine. NAT 8729 (45% w / w) was planed and added to a mixture of polyethylene glycol E200 (50% w / w) and polyethylene glycol E400 (5% w / w), both from Dow Corning . The substrate solution was then capped and mixed slowly with a special decomposition head impeller at 800 rpm and slightly heated. The temperature is not higher than 40°C. Typical mixing time is 5 hours. The final solution was a clear, viscous amber solution without precipitation or stratification.

[0019] To this base solution (97.25% w / w) was then mixed Dow Corning Fluid 190 (1.00% w / w) [a siliconized polyether comprising dimethyl, methyl(propylpolyoxyethyleneoxypropylene, ethyl ester) silicone]; Dow Corning silicone fluid (1.00% w / w) code 200-5 o...

Embodiment 2

[0024] A stable insulin composition is formulated by first preparing a matrix solution. Weigh polyethylene glycol E200 (PEG-200) (50% w / w) and add polyethylene glycol E400 (PEG-400) (5% w / w) to the same container to obtain the desired weight (Both provided by Dow Corning). PEG-200 and PEG-400 were slowly mixed (speed 1) at 38-40° C. with IKA model RW20 using a decomposition head impeller at 800 rpm to obtain a PEG-200 / PEG-400 solution. The PPC-rich phosphatidylcholine material designated NAT 8729 from Rhne-Poulenc contained 80.6% PPC-rich phosphatidylcholine and 4.9% lysophosphatidylcholine. Planed NAT 8729 (45% w / w) and added to the PEG-200 / PEG-400 solution, capped and mixed at a temperature not exceeding 40°C until a clear, viscous amber solution was obtained without precipitation or separation. layer appears. The mixing time is about 5 hours. An alternative mixture can be prepared by capping and mixing the above solution overnight without heat to give 95-96% yield. The...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

A method of delivering a drug composition comprises providing a carrier having a phosphatidylcholine component and a drug entrapped therein, and applying the composition to the skin for transdermal delivery of the drug, wherein the composition is stable.

Description

field of invention [0001] The present invention relates to topical drug delivery compositions and methods of transdermal drug delivery. More specifically, the present invention relates to stable drug delivery compositions for topical administration. Background of the invention [0002] Topical drug delivery systems are well known. These systems deliver drugs, therapeutic agents, and other desired substances transdermally, and can be designed to act locally at the site of application or systemically once in the blood circulation of the body. In these systems, delivery can be achieved by direct topical application of the substance or drug in the form of an ointment, etc., or by adhesion of a patch with a reservoir to hold the drug and apply it to the skin in a time-controlled manner. freed. [0003] Transdermal delivery systems for agents such as drugs, pain relieving compounds, vitamins, and skin improving compounds have been used for many years. These transdermal deliver...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61F13/00A61KA61K9/127A61K47/06
CPCA61K9/127A61K9/0014A61P3/10A61K47/06
Inventor 尼古拉斯·V·佩里科恩奇姆·波蒂尼
Owner TRANSDERMAL BIOTECHNOLOGY INC